– Single Doses of Investigational Zilebesiran Resulted in Sustained Serum Angiotensinogen and Blood Pressure Reductions Through Six Months, Supporting Quarterly and Potentially Biannual Dosing –

– Zilebesiran was Generally Well Tolerated, With No Treatment-Related Serious Adverse Events or Study Withdrawals, Supporting Continued Developmen

RNAi 降压3个月一次估计没啥问题，冲一冲半年$阿里拉姆制药(ALNY)$